Dalfampridine has 7 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Abacavir Sulfate, Dolutegravir Sodium, Lamivudine, Dolutegravir Sodium And Rilpivirine Hydrochloride, Cimetidine. Patients taking Dalfampridine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 7
- Contraindicated
- 2
- Major
- 4
- Moderate
- 1
Contraindicated (2)
- Dalfampridine + Abacavir Sulfate, Dolutegravir Sodium, Lamivudine— Dolutegravir inhibits OCT2 and potentially MATE1, may increase plasma concentrations of dalfampridine.
- Dalfampridine + Dolutegravir Sodium And Rilpivirine Hydrochloride— Dolutegravir inhibits OCT2 and MATE1, increasing dalfampridine plasma concentrations. Consider alternatives due to risk …
Major (4)
- Dalfampridine + Cimetidine— OCT2 inhibitor; concurrent use may increase dalfampridine exposure and elevate seizure risk.
- Dalfampridine + Dolutegravir Sodium— Dolutegravir may increase plasma concentrations of dalfampridine via OCT2 or MATE1 inhibition, potentially leading to se…
- Dalfampridine + Dolutegravir Sodium And Lamivudine— Dolutegravir inhibits renal OCT2 and MATE1 transporters, which may increase plasma concentrations of dalfampridine.
- Dalfampridine + Trilaciclib— COSELA inhibits OCT2 and may increase dalfampridine blood levels, elevating risk of seizures.
Moderate (1)
- Dalfampridine + Pyridostigmine Bromide— Concomitant administration delays the onset of action of pyridostigmine bromide.